At the news
? NEUTRALIMPACT 3/10 6-K filed Sep 1, 2026 at 07:36 ET
AstraZeneca's wholly owned subsidiary, AstraZeneca Finance LLC, has admitted EUR 2.55 billion in four tranches of fixed-rate notes to trading on the London Stock Exchange. This is a routine debt capital markets transaction to refinance or fund general corporate purposes, with no new material operational or financial information disclosed for the common equity. The offering is credit-neutral for the common stock, as it adds leverage but at moderate fixed rates and extends the maturity profile.
- AstraZeneca Finance LLC issued EUR 2.55 billion aggregate nominal amount of notes across four tranches.
- Tranches: EUR 700M 3.402% notes due 2030, EUR 600M 3.652% notes due 2032, EUR 500M 3.923% notes due 2035, EUR 750M 4.169% notes due 2038.
- All notes admitted to trading on the London Stock Exchange's Main Market on 1 September 2026.
- Issuance is under a base prospectus dated 9 June 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access